Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2270 participants.

Also called NCT03968393

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,270 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03968393
  • EU CT 2023-509142-35-00
  • EudraCT 2019-001336-62
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Denmark, Finland, Germany, India, Italy, Nepal, Netherlands, Pakistan, South Korea, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03968393. Randomized; single masking; primary purpose prevention. Start 2019-06-14 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Acronym
ASPIRE-AF
Condition
Stroke
Intervention (Drug)
Non-vitamin K oral anticoagulant (NOAC)
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Hamilton Health Sciences Corporation (class: other)

Record details

Record id
cardio:ct-nct03968393
Content hash
6d948720d90d816b95de10506f0b5c3e9a488764b1008d9de619a8a2f38fc070